ChemoCentryx Inc. (NASDAQ:CCXI)’s share price traded up 4.9% during mid-day trading on Friday . The stock traded as high as $4.35 and last traded at $4.31, with a volume of 182,136 shares changing hands. The stock had previously closed at $4.11.

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. reissued a “buy” rating and issued a $11.00 price objective on shares of ChemoCentryx in a research note on Tuesday, August 9th. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. Finally, Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The company has a 50 day moving average of $4.56 and a 200-day moving average of $3.77. The firm’s market cap is $206.33 million.

In other news, Director Thomas A. Edwards acquired 50,000 shares of ChemoCentryx stock in a transaction that occurred on Tuesday, May 17th. The shares were purchased at an average cost of $4.05 per share, for a total transaction of $202,500.00. Following the completion of the purchase, the director now directly owns 91,977 shares of the company’s stock, valued at approximately $372,506.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas A. Edwards acquired 25,000 shares of ChemoCentryx stock in a transaction that occurred on Monday, May 16th. The shares were purchased at an average price of $4.05 per share, for a total transaction of $101,250.00. Following the completion of the purchase, the director now directly owns 41,977 shares of the company’s stock, valued at $170,006.85. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in ChemoCentryx stock. Westfield Capital Management Co. LP boosted its stake in ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned 2.50% of ChemoCentryx worth $8,929,000 as of its most recent SEC filing.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.